ArticleBMC cancer2025
Distinct clinical features and epidemiological trends of very early and middle-aged early onset colorectal cancer based on SEER 17 and GBD 2021 data over the past 15 years.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early-Onset Metastatic Colorectal Adenocarcinoma Incidence and Survival Among Patients Younger Than 50 Years.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of early-onset colorectal cancer (EOCRC) is rapidly increasing. There may be differences in pathological characteristics and epidemiological trends between different subgroups of EOCRC, which warrants further investigation. MATERIALS: We utilized the Surveillance, Epidemiology, and End Results (SEER) 17 database and the Global Burden of Disease (GBD) 2021 data to analyze clinical, prognostic, and epidemiological differences by dividing EOCRC into Very Early Onset Colorectal Cancer (VEOCRC, ages 15-29) and Mid-Aged Early Onset Colorectal Cancer (MAEOCRC, ages 30-49) over the past 15 years. Statistical analyses included Kaplan-Meier survival analysis, joinpoint regression, average annual percentage change (AAPC) analysis, decomposition analysis.
resultsThe VEOCRC group had a significantly higher proportion of mucinous adenocarcinoma/signet ring cell carcinoma (MA/SRCC) (18.1% vs. 8.7%) and more advanced histologic grades III and IV (32.2% vs. 18.9%) compared to MAEOCRC. There were no significant pathological differences between MAEOCRC and Late-onset CRC (LOCRC). VEOCRC had a worse prognosis than MAEOCRC, especially at stage III. From 2006 to 2021, the age-standardized incidence rate (ASIR) for VEOCRC grew faster than for MAEOCRC globally (AAPC: 0.78 vs. 0.63), notably in high-middle Socio-demographic Index (SDI) countries (AAPC: 2.01 vs. 1.44). Excluding carcinoid tumors, the incidence of VEOCRC in high SDI countries has remained stable over the past 15 years, whereas in high-middle SDI countries, it surpassed high SDI countries as early as 2013, reaching the highest globally. Decomposition analysis revealed that in high-middle SDI countries, epidemiological changes contributed more to the increase in VEOCRC compared to MAEOCRC.
conclusionsVEOCRC and MAEOCRC differ significantly in clinical characteristics, prognosis, and epidemiology, with VEOCRC showing worse pathology and prognosis. In the past 15 years, the global incidence of VEOCRC has risen faster than MAEOCRC, warranting particular attention from policymakers, especially in high-middle SDI countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.